NICE. (v) Healthwatch England and Local Healthwatch; (vi) the General Medical Council; (vii) the General Dental Council; (viii) the General Optical Council; (ix) the General Pharmaceutical Council; (x) the Healthcare Safety Investigation Branch; and (xi) the Information Commissioner; Relevant Information means the Personal Data and Non-Personal Data processed under the Delegation and this Agreement, and includes, where appropriate, “confidential patient information” (as defined under section 251 of the NHS Act), and “patient confidential information” as defined in the 2013 Report, The Information Governance Review – “To Share or Not to Share?”);
NICE may assign this EULA without your consent (i) in connection with a merger, acquisition or sale of all or substantially all of our assets, or (ii) to any affiliate or as part of a corporate reorganization; and effective upon such assignment, the assignee is deemed substituted for NICE as a party to this EULA and NICE is fully released from all of its obligations and duties to perform under this EULA. Subject to the foregoing, this EULA will be binding upon, and inure to the benefit of the parties and their respective permitted successors and assigns.
NICE. ≤ (1 −θ)q[ pG (µG − µB )( X +σG ) + (1 − pG )δ (µG − µB )( x −σG ) − I1]. (25)Recalling that in the text.Γ = pG ( X +σG ) +(1 − pG )( x −σG ) , this constraint can be rewritten ascˆECase B: Firm Requests Added Investment – In the same manner, we can deriveΠ r,ne ≡ θ p [µ( X +σ ) − L* − L* ] + (1 −θ) p [µ( X +σ ) − L′ − L* ] , (26)i G GG B TR R R B TwhereLB′= qLˆB′+ (1 −~′q)LBas before, butLˆB′is defined as the solution to LpB BB* + (1 − p )δ µ ( x −σB B~′) = pRLˆB′+ (1 − pR)δ µR( x −σR) − I1, (27)TBRand LB is defined as the solution topB [µB
NICE. Initial dose Initiating treatment: 500mg od for the first week, 500mg bd for the second week, 1g morning and 500mg evening for the third week, then 1g bd. Consider lower doses if renal or hepatic impairment or older person. Duration of therapy is indefinite. May be stopped on specialist advice after prolonged period of disease remission. Response to treatment is usually seen within 3 months. Maintenance dose Usual maintenance dose is 1g bd. Maximum dose Occasionally higher doses are used up to a maximum of 3g daily. Monitoring: Baseline (Hospital) FBC, LFT, U&E, Creatinine, GFR, Chest X-ray within the last 6 months, CRP Initial (hospital) until patient stabilised FBC LFT, albumin, U&E Every two weeks until dose and monitoring is stable. Monthly thereafter for 3 months and if stable continue with 2 monthly monitoring. Routine (GP) After stabilisation period: FBC, LFT, albumin, U&E 2 monthly Any increase in dose FBC, U&E, LFT, albumin every 2 weeks until stable dose for 6 weeks then back to previous schedule Indications of when to withhold treatment and seek advice from the Specialist Test/ Indicator Result Additional action WBC <3.5 x 109/L Neutrophils <2.0 x 109/L Platelets <150 x 109/L ALT >100 units/L MCV >105 fL Check B12, folate and TSH. If abnormal treat any underlying abnormality. If normal, discuss with specialist team. Unexplained fall in albumin Creatinine>30% above baseline +/- GFR<60